Literature DB >> 26354066

Cross-cultural adaptation and validation of the Behcet's Disease Current Activity Form in Korea.

Hyo Jin Choi1, Mi Ryoung Seo1, Hee Jung Ryu1, Han Joo Baek1.   

Abstract

BACKGROUND/AIMS: This study was undertaken to perform a cross-cultural adaptation of the Behcet's Disease Current Activity Form (BDCAF, version 2006) questionnaire to the Korean language and to evaluate its reliability and validity in a population of Korean patients with Behcet's disease (BD).
METHODS: A cross-cultural study was conducted among patients with BD who attended our rheumatology clinic between November 2012 and March 2013. There were 11 males and 35 females in the group. The mean age of the participants was 48.5 years and the mean disease duration was 6.4 years. The first BDCAF questionnaire was completed on arrival and the second assessment was performed 20 minutes later by a different physician. The test-retest reliability was analyzed by computing κ statistics. Kappa scores of > 0.6 indicated a good agreement. To assess the validity, we compared the total BDCAF score with the patient's/clinician's perception of disease activity and the Korean version of the Behcet's Disease Quality of Life (BDQOL).
RESULTS: For the test-retest reliability, good agreements were achieved on items such as headache, oral/genital ulceration, erythema, skin pustules, arthralgia, nausea/vomiting/abdominal pain, and diarrhea with altered/frank blood per rectum. Moderate agreement was observed for eye and nervous system involvement. We achieved a fair agreement for arthritis and major vessel involvement. Significant correlations were obtained between the total BDCAF score with the BDQOL and the patient's/clinician's perception of disease activity p < 0.05).
CONCLUSIONS: The Korean version of the BDCAF is a reliable and valid instrument for measuring current disease activity in Korean BD patients.

Entities:  

Keywords:  Behcet syndrome; Behcet’s Disease Current Activity Form; Cross-cultural adaptation

Mesh:

Year:  2015        PMID: 26354066      PMCID: PMC4578035          DOI: 10.3904/kjim.2015.30.5.714

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


INTRODUCTION

Behcet’s disease (BD) is a chronic, multisystemic disorder affecting the mucous membranes, skin, eyes, blood vessels, nerves, and other bodily organs [1,2]. It has proved difficult to define the disease activity in BD because of its fluctuating course, the lack of laboratory tests reflecting disease severity, and the availability of only a few validated forms of BD activity. To evaluate BD activity, the English language questionnaire comprising the Behcet’s Disease Current Activity Form (BDCAF) was first created in 1999 [3,4], and later revised (http://www.behcet.ws). This current study was conducted to perform a cross-cultural adaptation of the BDCAF (version 2006) to the Korean language and to evaluate its reliability and validity in Korean patients with BD.

METHODS

Study subjects

Patients with BD who visited our rheumatology clinic were enrolled in this study, and the data from those patients who agreed to participate were collected prospectively from November 2012 until March 2013. All patients were older than 18 years and fulfilled the criteria of the International Study Group for Behcet’s Disease [5] or Chang’s criteria [6]. All patients provided written informed consent for participation in this study, and the Institutional Review Board of Gachon University Gil Medical Center approved the study protocol.

Cross-cultural adaptation

The total BDCAF score was calculated out of 12 and was given as a transformed index score on an interval scale. The questions relating to the patient’s perception of disease activity over the previous 4 weeks, the patient’s visual analogue scale (VAS) consisting of seven different facial expressions (on a scale of 1 to 7), and the clinician’s overall perception of disease activity (scale 1 to 7), were also recorded. Cross-cultural adaptation was performed according to the guidelines proposed by Beaton et al. [7] and Guillemin et al. [8] after obtaining permission to use the BDCAF by the developer. Translation into Korean language was carried out at the Department of Rheumatology, Gachon University Gil Medical Center. The two different translators, who were aware of the objectives of the study, performed the primary translation into the Korean language. The questionnaire was then back-translated into English by two different English teachers acting as independent translators who were unaware of the study objectives. The investigators discussed the discrepancies between the translation and back-translation of the questionnaire several times before it was finalized.

Study survey

The first BDCAF questionnaire was administered to the patient during his or her visit to the rheumatology clinic (time 1), and the second BDCAF was completed 20 minutes later (time 2). In addition, two different physicians asked the patient various questions relating to 12 items that concerned the overall perception of disease activity at time 1 and time 2. The clinician’s overall perception of disease activity was also recorded at both times. The questionnaire required approximately 5 to 10 minutes to complete. The Behcet’s Disease Quality of Life (BDQOL) was developed by Gilworth et al. [9] to assess the quality of life in BD patients. Its Arabic version [10], and the Korean version by Yi et al. [11] have been validated previously. The BDQOL consists of 30 questions regarding quality of life (score range 0 to 30). We obtained permission from the developer to use the Korean version of the BDQOL. At each BDCAF assessment, the BDQOL-K was also taken.

Statistical analysis

The agreement between the first and second assessments was evaluated by calculating the κ statistics. A κ score higher than 0.6 is considered to be a good agreement, 0.41 to 0.6 as moderate agreement, 0.21 to 0.4 as fair agreement, and below zero as poor agreement. The agreements between the BDCAF score, patient’s/physician’s VAS, and the BDQOL were calculated by the intraclass correlation coefficient (ICC) method. A p < 0.05 was considered to indicate statistical significance. Statistical analysis was performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

Clinical characteristics of patients

Forty-six patients were enrolled in this study. Seventy-six percent of the patients (n = 35) were female. The mean age was 48.5 years, and the mean disease duration was 6.4 years. The most common patient occupation was housewife (56.5%), and 40 patients (87.0%) had a spouse. Patients had most commonly undergone between 9 and 12 years of education (39.1%) (Table 1). The mean of the patient’s VAS was 3.5 at both times, and that of the physician was 3.0, which increased to 3.2 at time 2. The mean transformed BDCAF score was 6.6, which decreased to 6.2 at time 2, and the mean BDQOL score was 7.7, which also decreased to 7.0 at time 2 (Table 2).
Table 1.

Demographic characteristics of the patients (n = 46)

CharacteristicValue
Age, yr48.5 ± 11.5
Sex, male: female11:35
Disease duration, yr6.4 ± 4.7
Occupation
 Student2 (4.3)
 Housewife26 (56.5)
 Office job2 (4.3)
 Self-employed5 (10.9)
 Education/public officer3 (6.5)
 Others2 (4.3)
 Unemployed3 (6.5)
Marital status
 Unmarried/single3 (6.5)
 Married40 (87.0)
Level of education, yr
 ≤ 98 (17.4)
 9 < & ≤ 1218 (39.1)
 12 < & ≤ 1613 (28.3)
 > 161 (2.2)

Values are presented as mean ± SD or number (%).

Table 2.

Clinical characteristics of the patients (n = 46)

CharacteristicFirst assessmentSecond assessment
Patient’s VAS3.5 ± 1.43.5 ± 1.5
Physician’s VAS3.0 ± 1.23.2 ± 1.6
BDCAF score (transformed)6.6 ± 3.66.2 ± 3.2
BDQOL score7.7 ± 7.57.0 ± 7.5

Values are presented as mean ± SD.

VAS, visual analogue scale (1 to 7); BDCAF, Behcet’s Disease Current Activity Form; BDQOL, Behcet’s Disease Quality of Life (0 to 30).

The test-retest reliability and validity of BDCAF

The agreement between items in the BDCAF 1 and 2 is shown in Table 3. Good agreements were achieved (κ scores > 0.6) for headache, oral/genital ulceration, erythema, skin pustule, arthralgia, nausea/vomiting/abdominal pain, and diarrhea with altered/frank blood per rectum. Moderate agreement was observed for eye and nervous system involvement. We obtained a fair agreement for arthritis and major vessel involvement (Table 3).
Table 3.

The agreement between the first and second questionnaires of the Behcet’s Disease Current Activity Form

Variableκp value
Headache0.774< 0.001
Oral ulceration0.869< 0.001
Genital ulceration0.832< 0.001
Erythema0.617< 0.001
Skin pustules0.835< 0.001
Joints (arthralgia)0.781< 0.001
Joints (arthritis)0.3550.014
Nausea/vomiting/abdominal pain0.801< 0.001
Diarrhea with altered/frank blood per rectum0.844< 0.001
Eye involvement0.4270.003
Nervous system involvement0.502< 0.001
Major vessel involvement0.3300.022
The test-retest reliability of the BDCAF score was good, with a high correlation between the two time points (ICC = 0.836, p < 0.001). The BDCAF 1 score significantly correlated with the BDQOL (ICC = 0.478, p = 0.016) at time 1, and the BDCAF 2 score also correlated with the patient’s VAS (ICC = 0.311, p = 0.025), physician’s VAS (ICC = 0.362, p = 0.005), and the BDQOL (ICC = 0.529, p = 0.007) at time 2 (Table 4).
Table 4.

The Intraclass correlation coefficient between the Behcet’s Disease Current Activity Form score and other variables

Evaluated timeIntraclass correlation coefficients
95% Confidence interval
First BDCAFSecond BDCAF
BDCAF score
 First0.836[a]0.703 to 0.909
 Second0.836[a]0.703 to 0.909
Patient’s VAS
 First0.146–0.228 to 0.449
 Second0.311[a]–0.150 to 0.604
Physician’s VAS
 First0.116–0.206 to 0.403
 Second0.362[a]–0.169 to 0.661
BDQOL score
 First0.478[a]0.060 to 0.711
 Second0.529[a]0.149 to 0.740

BDCAF, Behcet’s Disease Current Activity Form; VAS, visual analogue scale (1 to 7); BDQOL, Behcet’s Disease Quality of Life (0 to 30).

p < 0.05.

DISCUSSION

We undertook this study to assess the cross-cultural adaptation of the revised BDCAF questionnaire in Korean patients with BD. The reliability and validity tests showed a successful adaptation of the BDCAF into the Korean language. BD presents with a heterogeneous nature of organ involvement and has a fluctuating course [1]. There is also a lack of laboratory tests that give information on the severity of the disease [1-3]. The clinical instrument for reflecting the overall disease activity for BD was designed in the United Kingdom in 1999 and subsequently revised in 2006. This BDCAF (English version) should be used for cross-cultural adaptation as an instrument for assessing disease severity within different cultures and languages. In the present study, good agreements (κ scores > 0.6) were obtained in most of the items. In the original United Kingdom version [3], good agreement was also obtained for all BDCAF variables, except for the questions relating to diarrhea with altered or frank blood and new large vessel involvement. The lack of agreement for bloody diarrhea in the United Kingdom version was attributed to the difficulty in determining whether or not this symptom relates to mucosal inflammation, when based only on the information gained from the clinical history. On the other hand, in the Turkish version of the BDCAF, good interobserver agreement was obtained for these two items involving gastrointestinal symptoms [12]. In our study, we had good agreements for nausea/vomiting/abdominal pain and diarrhea with altered/frank blood per rectums. Our study demonstrated moderate agreement for eye and nervous system involvement. A similar result for eye involvement was reported in the Brazilian study [13]. For a proper assessment of eye involvement in BD, cooperation with ophthalmologists should be arranged. We had fair agreement for arthritis and major vessel involvement. However, these questions might be limited by the information gained from history-taking alone. The small number of patients in our study could also affect the results, as in a previous report [13]. For example, only two patients were found to have major vessel involvement by both physicians. There were significantly positive correlations between the total BDCAF scores and the BDQOL at time 1, and the patient’s VAS, physician’s VAS, and the BDQOL at time 2, which therefore represent the reliability and reproducibility of our study. In conclusion, the cross-cultural adaptation of the BDCAF questionnaire for use in Korea was successful. The Korean version of the BDCAF is a reliable and valid instrument for measuring current disease activity in BD patients, especially for the items relating to headache, mucocutaneous, musculoskeletal, and gastrointestinal involvements. The Korean version of the BDCAF can be used in Korean patients as a simple instrument for assessing clinical BD activity. 1. Cross-cultural adaptation of the Behcet’s Disease Current Activity Form (BDCAF) questionnaire for use in Korea was performed. 2. There were good agreements and correlations between the BDCAF score and the Behcet’s Disease Quality of Life score, and the patient’s/clinician’s perception of disease activity in the Korean version of the BDCAF. 3. This a reliable and valid instrument for measuring current disease activity in Behcet’s disease patients.
  13 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 2.  Guidelines for the process of cross-cultural adaptation of self-report measures.

Authors:  D E Beaton; C Bombardier; F Guillemin; M B Ferraz
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-15       Impact factor: 3.468

3.  Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome.

Authors:  V Hamuryudan; I Fresko; H Direskeneli; M J Tenant; S Yurdakul; T Akoglu; H Yazici
Journal:  Rheumatology (Oxford)       Date:  1999-08       Impact factor: 7.580

4.  Behçet's disease: evaluation of a new instrument to measure clinical activity.

Authors:  B B Bhakta; P Brennan; T E James; M A Chamberlain; B A Noble; A J Silman
Journal:  Rheumatology (Oxford)       Date:  1999-08       Impact factor: 7.580

5.  The Behcet's disease activity index.

Authors:  G Lawton; B B Bhakta; M A Chamberlain; A Tennant
Journal:  Rheumatology (Oxford)       Date:  2003-07-30       Impact factor: 7.580

6.  Development of the BD-QoL: a quality of life measure specific to Behçet's disease.

Authors:  Gill Gilworth; M Anne Chamberlain; Bipin Bhakta; Dorian Haskard; Alan Silman; Alan Tennant
Journal:  J Rheumatol       Date:  2004-05       Impact factor: 4.666

Review 7.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 8.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

9.  Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.

Authors:  F S Neves; J C B Moraes; S C Kowalski; C Goldenstein-Schainberg; L V Lage; C R Gonçalves
Journal:  Clin Rheumatol       Date:  2006-12-20       Impact factor: 3.650

10.  Survey and validation of the criteria for Behcet's disease recently used in Korea: a suggestion for modification of the International Study Group criteria.

Authors:  Hyun Kyu Chang; Seung Yong Kim
Journal:  J Korean Med Sci       Date:  2003-02       Impact factor: 2.153

View more
  5 in total

1.  Validity and reliability of a checklist for patients with Behçet's disease based on the International Classification of Functioning, Disability and Health.

Authors:  Hideyo Tsutsui; Hirotoshi Kikuchi; Hiroko Oguchi; Hajime Kono; Takayoshi Ohkubo
Journal:  Rheumatol Int       Date:  2021-09-22       Impact factor: 2.631

Review 2.  Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.

Authors:  Joanna C Robson; David Jayne; Peter A Merkel; Jill Dawson
Journal:  Patient Relat Outcome Meas       Date:  2019-02-08

3.  Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease.

Authors:  Marta Arbrile; Massimo Radin; Daniela Rossi; Elisa Menegatti; Simone Baldovino; Savino Sciascia; Dario Roccatello
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

4.  Validation and reliability of a Behcet's Syndrome Activity Scale in Korea.

Authors:  Hyo Jin Choi; Mi Ryoung Seo; Hee Jung Ryu; Han Joo Baek
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

5.  CXCL10/CXCR3 axis is associated with disease activity and the development of mucocutaneous lesions in patients with Behçet's disease.

Authors:  Sang Jin Lee; Shin Eui Kang; Eun Ha Kang; Byoong Yong Choi; Katherine Masek-Hammerman; Jameel Syed; Yutian Zhan; Kathleen Neff-Phillips; Jin Kyun Park; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.